Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
These included eicosapentaenoic acid plus docosahexaenoic acid (EPA + DHA), SAMe, curcumin, saffron, carnitine, vitamin D, zinc, and magnesium, indicating that these nutraceuticals were more effective whether employed as monotherapy or as an adjunct to ADT, as opposed to ADT alone (Figure 3).Network diagram for change in depressive symptoms. a Lines between nodes represent direct comparisons between trials, and the circle size is proportional to the size of the population that received each treatment.
Source: Primary outcome: changes in scores on the depression rating scale. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Systematic review.
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Comparative efficacy and tolerability of nutraceuticals for depressive disorder: A systematic review and network meta-analysis
Source: Article title.
Comparative efficacy and tolerability of nutraceuticals for depressive disorder: A systematic review and network meta-analysis
Source: Article title.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Comparative efficacy and tolerability of nutraceuticals for depressive disorder: A systematic review and network meta-analysis
Systematic review · Psychological Medicine · 2025
Original publication title
Comparative efficacy and tolerability of nutraceuticals for depressive disorder: A systematic review and network meta-analysis
© The Author(s) 2025
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Nutraceuticals have been taken as an alternative and add-on treatment for depressive disorders. Direct comparisons between different nutraceuticals and between nutraceuticals and placebo or antidepressants are limited. Thus, it is unclear which nutraceuticals are the most efficacious.
Source: BackgroundAbstract: What methods does the paper describe?
We conducted a network meta-analysis to estimate the comparative efficacy and tolerability of nutraceuticals for the treatment of depressive disorder in adults. The primary outcome was the change in depressive symptoms, as measured by the standard mean difference (SMD). Secondary outcomes included response rate, remission rate, and anxiety. Tolerability was defined as all-cause discontinuation and adverse events. Frequentist random-effect NMA was conducted.
Source: MethodsAbstract: Results
Hundred and ninety-two trials involving 17,437 patients and 44 nutraceuticals were eligible for inclusion. Adjunctive nutraceuticals consistently showed better efficacy than antidepressants (ADT) alone in outcomes including SMD, remission, and response. Notable combinations were Eicosapentaenoic acid + Docosahexaenoic Acid plus ADT (EPA + DHA + ADT) (SMD 1.04, 95% confidence interval 0.64 to 1.44), S-Adenosyl Methionine (SAMe) + ADT (0.99, 0.31 to 1.68), curcumin + ADT (1.03, 0.55 to 1.51), Zinc + ADT (1.59, 0.63 to 2.55), tryptophan + ADT (1.24, 0.32 to 2.16), and folate + ADT (0.64, 0.17 to 1.10).
Additionally, four nutraceutical monotherapies demonstrated superior efficacy compared to ADT: EPA + DHA (0.6, 0.32 to 0.88), SAMe (0.52, 0.18 to 0.87), curcumin (0.62, −0.17 to 1.40) and saffron (0.69, 0.34 to 1.04). It is noted that EPA + DHA, SAMe, and curcumin showed strong performance as either monotherapies or adjuncts to ADT. Most nutraceuticals showed comparable tolerability to placebo.
Source: ResultsAbstract: Conclusions
This extensive systematic review and NMA of nutraceuticals for treating depressive disorders indicated a number of nutraceuticals that could offer benefits, either as adjuncts or monotherapies.
Source: ConclusionsAuthors’ abstract
Background
Nutraceuticals have been taken as an alternative and add-on treatment for depressive disorders. Direct comparisons between different nutraceuticals and between nutraceuticals and placebo or antidepressants are limited. Thus, it is unclear which nutraceuticals are the most efficacious.
Methods
We conducted a network meta-analysis to estimate the comparative efficacy and tolerability of nutraceuticals for the treatment of depressive disorder in adults. The primary outcome was the change in depressive symptoms, as measured by the standard mean difference (SMD). Secondary outcomes included response rate, remission rate, and anxiety. Tolerability was defined as all-cause discontinuation and adverse events. Frequentist random-effect NMA was conducted.
Results
Hundred and ninety-two trials involving 17,437 patients and 44 nutraceuticals were eligible for inclusion. Adjunctive nutraceuticals consistently showed better efficacy than antidepressants (ADT) alone in outcomes including SMD, remission, and response. Notable combinations were Eicosapentaenoic acid + Docosahexaenoic Acid plus ADT (EPA + DHA + ADT) (SMD 1.04, 95% confidence interval 0.64 to 1.44), S-Adenosyl Methionine (SAMe) + ADT (0.99, 0.31 to 1.68), curcumin + ADT (1.03, 0.55 to 1.51), Zinc + ADT (1.59, 0.63 to 2.55), tryptophan + ADT (1.24, 0.32 to 2.16), and folate + ADT (0.64, 0.17 to 1.10).
Additionally, four nutraceutical monotherapies demonstrated superior efficacy compared to ADT: EPA + DHA (0.6, 0.32 to 0.88), SAMe (0.52, 0.18 to 0.87), curcumin (0.62, −0.17 to 1.40) and saffron (0.69, 0.34 to 1.04). It is noted that EPA + DHA, SAMe, and curcumin showed strong performance as either monotherapies or adjuncts to ADT. Most nutraceuticals showed comparable tolerability to placebo.
Conclusions
This extensive systematic review and NMA of nutraceuticals for treating depressive disorders indicated a number of nutraceuticals that could offer benefits, either as adjuncts or monotherapies.
Publication and source details
Original title: Comparative efficacy and tolerability of nutraceuticals for depressive disorder: A systematic review and network meta-analysis
Ying-Chih Cheng; Wei-Lieh Huang; Wen-Yin Chen; Yu-Chen Huang; Po-Hsiu Kuo; Yu-Kang Tu
Psychological Medicine · 2025
Corresponding authors: Po-Hsiu Kuo and Yu-Kang Tu; Emails: phkuo@ntu.edu.tw; yukangtu@ntu.edu.tw © The Author(s) 20252025The Author(s)https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited. Ministry of Science and Technology, Taiwanhttp://dx.doi.org/10.13039/501100004663 MOST 108-2314-B-002-136-MY3Po-Hsiu KuoRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T05:24:58.930657+00:00
DOI: 10.1017/s0033291725000996 · PMC12094663